Opioid Side Effects and Their Treatment in Patients with Chronic Cancer and Noncancer Pain

REFERENCES

• American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th ed. American Pain Society, Glenview, IL 2003
   Google Scholar
• Ballantyne J C, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943–1953
   PubMed Web of Science ®Google Scholar
• Lötsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 2006; 121: 1–5
   PubMed Web of Science ®Google Scholar
• Stamer U M, Stüber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007; 20: 478–484
   PubMed Web of Science ®Google Scholar
• Furlan A D, Sandoval J A, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Can Med Assoc J 2006; 174: 1589–1594
   PubMed Web of Science ®Google Scholar
• Eisenberg E, McNicol E, Carr D B. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005; 293: 3043–3052
   PubMed Web of Science ®Google Scholar
• “Chronic Pain in America: Roadblocks to Relief,” a study conducted by Roper Starch Worldwide for American Academy of Pain Medicine. American Pain Society and Janssen Pharmaceutica. 1999, Available at http://www.ampainsoc.org/links/roadblocks/ Accessed February 26, 2008
   Google Scholar
• Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care 2006; 23: 229–235
   Google Scholar
• Moore R A, McQuay H J. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7: R1046–R1051
   PubMed Web of Science ®Google Scholar
• McNicol E, Horowicz-Mehler N, Fisk R A, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4: 231–256
   PubMed Web of Science ®Google Scholar
• Portenoy R K. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994; 23: 160–170
   PubMedGoogle Scholar
• Webster L R, Butera P G, Moran L V, Wu N, Burns L H, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006; 7: 937–946
   PubMed Web of Science ®Google Scholar
• Cherny N I. The management of cancer pain. Handbook of Pain Management, R Melzack, P D Wall. Churchill Livingstone, Edinburgh 2003; 641–667
   Google Scholar
• Mercadante S. Opioid rotation for cancer pain—rationale and clinical aspects. Cancer 1999; 86: 1856–1866
   PubMed Web of Science ®Google Scholar
• Yaksh T L. Tolerance: factors involved in changes in the dose-effect relationship with chronic drug exposure. Towards a New Pharmacotherapy of Pain, A I Basbaum, J M Besson. John Wiley & Sons, Chichester and New York 1991; 157–180
   Google Scholar
• McQuay H. Opioids in pain management. Lancet 1999; 353: 2229–2232
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manage 1997; 13: 254–261
   PubMed Web of Science ®Google Scholar
• Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews 2007; 4
   Google Scholar
• Sykes N P. Opioid bowel dysfunction in palliative care. Handbook of Opioid Bowel Syndrome, C S Yuan. Haworth Press, Binghamton, NY 2005; 69–100
   Google Scholar
• Mulrow C D, Williams J W, Jr, Trivedi M, et al. Treatment of Depression: Newer Pharmacotherapies. Agency for Health Care Policy and Research, Rockville, MD February, 1999, Evidence Report/Technology Assessment No. 7. (Prepared by the San Antonio Evidence-based Practice Center based at The University of Texas Health Science Center at San Antonio under Contract 290-97-0012.) AHCPR Publication No. 99-E014
   Google Scholar
• Pasero C, Portenoy R K, McCaffery M. Opioid analgesics. Pain, 2nd ed, M McCaffery, C Pasero. Mosby, St. Louis 1999; 161–299
   Google Scholar
• Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182(Suppl)11S–8S
   Google Scholar
• Fallon M, O'Neill B. ABC of palliative care. Constipation and diarrhoea. BMJ 1997; 315: 1293–1296
   Google Scholar
• Kalso E, Edwards J E, Moore R A, McQuay H J. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372–380
   PubMed Web of Science ®Google Scholar
• Twycross R G, McNamara P, Schuijt C, Kamm M A, Jordan C. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose ranging study. Pall Med 2006; 20: 419–423
   PubMed Web of Science ®Google Scholar
• McNicol E D, Boyce D, Schumann R, Carr D B. Mu-opioid antagonists for opioid-induced bowel dysfunction. The Cochrane Database of Systematic Reviews 2008, (2):CD006332
   Google Scholar
• Paulson D M, Kennedy D T, Donovick R A, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. J Pain 2005; 6: 184–192
   PubMed Web of Science ®Google Scholar
• Yuan C S, Foss J F, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283: 367–372
   PubMed Web of Science ®Google Scholar
• Data on file, Wyeth Pharmaceuticals
   Google Scholar
• Lawlor P G, Gagnon B, Mancini I L, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160: 786–794
   PubMed Web of Science ®Google Scholar
• Lawlor P G. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer 2002; 94: 1836–1853
   PubMed Web of Science ®Google Scholar
• Gaudreau J D, Gagnon P, Roy M A, Harel F, Tremblay A. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 2007; 109: 2365–2373
   PubMed Web of Science ®Google Scholar
• Abrahm J L. Advances in pain management for older adult patients. Clin Geriatr Med 2000; 16: 269–311
   PubMed Web of Science ®Google Scholar
• Schug S A, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf 1992; 7: 200–21
   PubMed Web of Science ®Google Scholar
• Morita T, Takigawa C, Onishi H, et al. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage 2005; 30: 96–103
   PubMed Web of Science ®Google Scholar
• Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manage 2004; 27: 268–273
   PubMedGoogle Scholar
• Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998; 74: 5–9
   PubMed Web of Science ®Google Scholar
• Lyss A P, Portenoy R K. Strategies for limiting side effects of cancer pain therapy. Semin Oncol 1997; 24: S16–S34
   PubMed Web of Science ®Google Scholar
• Hofmann A, Tangri N, Lafontaine A L, Postuma R B. Myoclonus as an acute complication of low-dose hydromorphone in multiple system atrophy. J Neurol Neurosurg Psychiatry 2006; 77: 994–995
   Google Scholar
• Glavina M J, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389–390
   PubMedGoogle Scholar
• Cartwright P D, Hesse C, Jackson A O. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manage 1993; 8: 492–495
   Google Scholar
• Rozan J P, Kahn C H, Warfield C A. Epidural and intravenous opioid-induced neuroexcitation. Anesthesiology 1995; 83: 860–863
   Google Scholar
• Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Cancer 2001; 9: 205–206
   Google Scholar
• Sussman G, Shurman J, Creed M R, et al. Intravenous ondansetron for the control of opioid-induced nausea and vomiting. Clin Ther 1999; 21: 1216–1227
   PubMed Web of Science ®Google Scholar
• Passik S D, Lundberg J, Kirsh K L, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526–532
   PubMed Web of Science ®Google Scholar
• Scotto di Fazano C, Vergne P, Grilo R M, Bertin P, Bonnet C, Treves R. Preventive therapy for nausea and vomiting in patients on opioid therapy for non-malignant pain in rheumatology. Therapie 2002; 57: 446–449
   Google Scholar
• Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer 2002; 10: 231–236
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Tsuneto S, Matsuda Y, et al. A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage 2007; 34: 217–222
   PubMed Web of Science ®Google Scholar
• Ballantyne J C, Loach A B, Carr D B. Itching after epidural and spinal opiates. Pain 1988; 33: 149–160
   PubMed Web of Science ®Google Scholar
• Chaney M A. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995; 42: 891–903
   PubMed Web of Science ®Google Scholar
• Schmelz M. Itch—mediators and mechanisms. J Dermatol Sci 2002; 28: 91–96
   PubMed Web of Science ®Google Scholar
• Kyriakides K, Hussain S K, Hobbs G J. Management of opioid-induced pruritus: a role for 5-HT3 antagonists?. Br J Anaesth 1999; 82: 439–441
   PubMed Web of Science ®Google Scholar
• Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16: 121–124
   PubMed Web of Science ®Google Scholar
• Acalovschi I, Bodolea C, Slabu L. Therapeutic effect of ondansetron and propofol on neuroaxial opioid-induced pruritus. Anesthesiology 1994; 81: 591–601
   Google Scholar
• O'Mahony S, Coyle N, Payne R. Current management of opioid-related side effects. Oncology 2000; 15: 61–77
   Google Scholar
• Estfan B, Mahmoud F, Shaheen P, et al. Respiratory function during parenteral opioid titration for cancer pain. Palliat Med 2007; 21: 81–86
   Google Scholar
• Walsh T D, Rivera N I, Kaiko R. Oral morphine and respiratory function amongst hospice inpatients with advanced cancer. Support Care Cancer 2003; 11: 780–784
   Google Scholar
• Wang D, Teichtahl H, Drummer O, et al. Central sleep apnea in stable methadone maintenance treatment patients. Chest 2005; 128: 1348–1356
   PubMed Web of Science ®Google Scholar
• Webster L R, Choi Y, Desai H H, Webster L, Grant B JB. Sleep-disordered breathing and chronic opioid therapy. Pain Med 2008; 9: 425–432
   PubMed Web of Science ®Google Scholar
• Teichtahl H, Prodromidis A, Miller B, Cherry G, Kronborg I. Sleep-disordered breathing in stable methadone programme patients: a pilot study. Addiction 2001; 96: 395–403
   PubMed Web of Science ®Google Scholar
• Dimsdale J E, Norman D, DeJardin D, Wallace M S. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3: 33–36
   PubMed Web of Science ®Google Scholar
• Walker J M, Farney R J, Rhondeau S M, Boyle K M, Cloward T V, Shilling K C. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007; 3: 455–461
   PubMed Web of Science ®Google Scholar
• Lipman A G. Methadone: a double edged sword. J Pain Palliat Care Pharmacother 2005; 19: 3–4
   Google Scholar
• White J M, Irvine R J. Mechanisms of fatal opioid overdose. Addiction 1999; 94: 961–972
   PubMed Web of Science ®Google Scholar
• van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006; 105: 51–57
   PubMed Web of Science ®Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence based report. J Clin Onc 2001; 19: 2542–2554
   PubMed Web of Science ®Google Scholar
• Slatkin N E, Rhiner M, Bolton T M. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manage 2001; 21: 425–438
   PubMed Web of Science ®Google Scholar
• McNamara P. Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliat Med 2002; 16: 425–434
   Google Scholar
• Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003; 26: 1049–1054
   Google Scholar
• Mercadante S, Calderone L, Villari P, et al. The use of pilocarpine in opioid-induced xerostomia. Palliat Med 2000; 14: 529–531
   Google Scholar
• White I D, Hoskin P J, Hanks G W, Bliss J M. Morphine and dryness of the mouth. BMJ 1989; 298: 1222–1223
   Google Scholar
• Gotrick B, Akerman S, Ericson D, Torstenson R, Tobin G. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res 2004; 83: 393–397
   Google Scholar
• Davies A N, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 2005; 30: 496–497
   PubMed Web of Science ®Google Scholar
• South S M, Smith M T. Analgesic tolerance to opioids. Pain: Clinical Updates 2001; IX(5), Available at http://www.iasp-pain.org/AM/TemplateRedirect.cfm?template=/CM/ContentDisplay.cfm&ContentID=2502 Accessed February 28, 2008
   Google Scholar
• Compton P, Charuvastra V C, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63: 139–146
   PubMed Web of Science ®Google Scholar
• Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100: 213–217
   PubMed Web of Science ®Google Scholar
• Daniell H W. Opioid-induced androgen deficiency discussion in opioid contracts. Am J Med 2007; 120: e21
   PubMed Web of Science ®Google Scholar
• Daniell H W. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 2008; 9: 28–36
   PubMed Web of Science ®Google Scholar
• Daniell H W, Lentz R, Mazer N A. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain 2006; 7: 200–210
   PubMed Web of Science ®Google Scholar
• Liebeskind J C. Pain can kill. Pain 1991; 44: 3–4
   PubMed Web of Science ®Google Scholar
• Vines S W, Gupta S, Whiteside T, Dostal-Johnson D, Hummler-Davis A. The relationship between chronic pain, immune function, depression, and health behaviors. Biol Res Nurs 2003; 5: 18–29
   PubMedGoogle Scholar
• Kornick C A, Kilborn M J, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003; 105: 499–506
   PubMed Web of Science ®Google Scholar
• Ehret G B, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166: 1280–1287
   PubMed Web of Science ®Google Scholar
• Krantz M J, Lewkowiez L, Hays H, Woodroffe M A, Robertson A D, Mehler P S. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137: 501–504
   PubMed Web of Science ®Google Scholar
• Atkinson D, Dunne A, Parker M. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user. Anaesthesia 2007; 62: 952–955
   PubMed Web of Science ®Google Scholar
• Goudas L C, Carr D B, Bloch R, et al. AHRQ Evidence Report on Management of Cancer Pain, Available at http://www.ahrq.gov/clinic/tp/canpaintp.htm Accessed February 28, 2008
   Google Scholar